Horizon Therapeutics (HZNP) Receives a Buy from BMO Capital

BMO Capital analyst Gary Nachman maintained a Buy rating on Horizon Therapeutics (HZNPResearch Report) today and set a price target of $145.00. The company’s shares closed last Friday at $83.61, close to its 52-week low of $78.75.

According to, Nachman ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -6.6% and a 42.2% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Bausch Health Companies, Aquestive Therapeutics, and Ionis Pharmaceuticals.

Horizon Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $132.33, representing a 60.2% upside. In a report issued on July 5, UBS also maintained a Buy rating on the stock with a $137.00 price target.

See the top stocks recommended by analysts >>

Horizon Therapeutics’ market cap is currently $19.16B and has a P/E ratio of 22.90.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Horizon Therapeutics Plc is a biopharmaceutical company, which is engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Rheumatology, and Inflammation segments. The Orphan and Rheumatology segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises of medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Read More on HZNP:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More